Given the severity, and relentless relapses of the disease, the push to develop efficient therapies and treatments to battle the disease and improve patient survival rates and quality of life, has been especially strong. Unfazed research and development activities, have over the years, resulted in commendable advances in treatment therapies and procedures. Although patients today have a broader choice of treatments than before, the objective of all the treatment therapies is to slower the growth of malignant myeloma cells rather than elimination, and offer palliative care such as, reduction in disease symptoms, such as, fatigue, anemia, bone pain, and recurrent infections, among others.

These and other market data and trends are presented in "Multiple Myeloma Therapeutics: US Market Trends & Analysis" by BizAcumen LLC. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

1.Methodology
- Study Reliability and Reporting Limitations
- Disclaimers
- Quantitative Techniques & Reporting Level
2.Market Overview
- Hematological Cancer Therapies: A Prelude
- Treatment Regimes: The Golden Rule
- Multiple Myeloma: A Second Most Common Hematological Cancer
- Treatment Therapies: Move up The Learning Curve
- Risk-Adapted Therapy: The New Norm of Future Treatment
- New Generation Drugs in The Arsenal against Multiple Myeloma
- Velcade® (Bortezomib)
- Thalomid® (Thalidomide)
- Revlimid® (Lenalidomide)
- Alkeran (Melphalan)
- Doxil (Liposomal Doxorubicin)
- Trisenox® (Arsenic Trioxide)
- Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons
- Revlimid Overtakes Thalomid: Why?
- How Effective Will Thalomid Be in The 3rd Line Setting? Skepticism Overflows...
- Revlimid Impedes Stem Cell Harvesting!!: What's The Truth?
1st & 2nd Generation Geldanamycin Analog to Do Wonders for Myeloma Treatment
- Other Trends & Issues
- Approval of New Generation Drugs Push The Market into The Bulge Bracket
- Growth Fundamentals Get Stronger
- Multidrug Resistance: A Challenge to Reckon with
- Gene Therapy Exudes Hope
- Challenges Encountered in Clinical Trials
- Fda's Antidotes
- Europe Lagging behind in Drug Approvals
- Market Share Statistics
- Oncology and Hematology Market
- Drugs Approved & in Pipeline: A Review
- Multiple Myeloma Drugs Approved by The Fda as of The Year 2008
- Multiple Myeloma Drugs in Pipeline in The US as of The Year 2008
- Phase Iii Drugs in Pipeline
- Phase Ii Drugs in Pipeline
- Phase I Drugs in Pipeline
- Key Non-Profit Organizations in The US
- Multiple Myeloma Research Foundation (Mmrf)
- National Coalition for Cancer Survivorship (Nccs)
- National Marrow Donor Program (Nmdp)
- Oregon Health and Science University Cancer Institute
3.Product Facts
- Drugs
- Lines of Treatment
4.Corporate Developments
- Nice Grants Approval for Use of Revlimid®
- Swog Announces Closure of Phase Iii Trial (S0232) for Paitents with Multiple Myeloma
- Cytrx to Acquire Innovive
- Launch of Epoetin Alfa Hexal
- Pdl and Bristol-Myers Signs Agreement
- Mnkd and Lls Conclude Joint Research Agreement
- Morphosys and Dsm Enter into Agreement
- Stemcyte Enters into Joint Venture with Cadila and Apollo Hospitals in India
- Immunocellular Acquires Molecular Antibody Technology
- US House of Representatives Sanction The Hematological Cancer Research Investment and Education Act
- Bayer and Cell Therapeutics Enter into Mutual Agreement
- Bristol-Myers to Take over Kosan Biosciences
- Bristol and Pdl Biopharma Enter into Agreement
- Gamida Cell Enters into A Agreement with Amgen
- Circadian Acquires Complete Stake in Vegenics
- Takeda Acquires Millennium Pharmaceuticals
- Fujimoto Pharmaceutical Receives Approval to Market Thalidomide
- Celgene Obtains Health Canada Approval for Revlimid Oral Cancer Drug
- Fda Grants Orphan-Drug Designation to Melphalan
- Merck Commences Phase Ii-B and Phase Iii Clinical Trial of Zolinza
- Clavis Initiates Phase Ii Trial of Elacytarabine
- Gilead Sciences Commences Gs 9219 Phase I Clinical Trial
- Astrazeneca Carries out Azd 0530 Phase Ii Trial
- European Commission Grants Approval of Thalidomide for Multiple Myeloma
- Emea Issues Positive Opinion for Thalidomide Use in Multiple Myeloma
- Global Regulatory Developments for The Use of Revlimid® in Multiple Myeloma
- Takeda Gains Fda Approval to Promote Velcade
- Health Canada Approves Velcade
- Genzyme Receives Fda Certification for Mozobil
- Celgene's Thalidomide Pharmion Receives Marketing Authorization
- Glaxosmithkline Forms Alliance with Oncomed for Developing Cancer Therapeutics
- Cyclacel Signs Agreement to Acquire Align Pharmaceuticals
- Biogen and Genentech to Jointly Develop and Commercialize New Blood Cancer Drug
- Aegera Therapeutics Acquires Lymphosign Inc
- Velcade Gains Subsidy
- Inex Pharmaceuticals Spins off Biotechnology Business into Tekmira Pharmaceuticals
- Millegen Enters into Collaboration with Lfb
- Access Pharmaceuticals to Acquire Somanta
- Topotarget to Acquire Apoxis Sa
- Genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics
- Celgene Agrees to Acquisition of Pharmion
- Perkinelmer Plans Acquisition of Viacell
- Favrille Announces Acquisition of Monoclonal Antibody Range from Diversa
- Johnson & Johnson Secures Contract worth US$112 Million
- Bioniche Pharma to Acquire Branded Pharmaceutical from Nabi Biopharmaceuticals
- Ziopharm Commences Phase Ii Clinical Trial of Zio-101
- Fda Approves Pluristem's Pre-Ind Application of Plx-I
- Merck Pharmaceuticals Commences Phase I Study for R763 Kinase Inhibitor
- Swissmedic Approves Celgene's Revlimid Oral Cancer Drug
- Celgene's Revlimid Receives Eu's Marketing Authorization
- Fda Approves Application of Piramal's Ind-P276 Multiple Myeloma Drug
- Millennium Pharmaceuticals and Johnson & Johnson Initiate Velcade® Phase Ii Trial
- Fda to Consider The New Drug Application Filed for Use of Doxil® Combined with Velcade® in Patients with Multiple Myeloma
- Ortho Biotech Files Application with Fda for Approval of Combination Drug Doxil® and Velcade®
- Caraco's Allopurinol Receives Fda Approval
5.Major Players
- Amgen Inc (USA)
- Bristol-Myers Squibb Company (USA)
- Kosan Biosciences, Inc. (USA)
- Celgene Corporation (USA)
- F. Hoffmann-La Roche Ltd Switzerland)
- Genentech, Inc. (USA)
- Genta Incorporated (USA)
- Millennium Pharmaceuticals (USA)
- Ortho Biotech Products, Lp (USA)
- Seattle Genetics (USA)
- Ziopharm Oncology, Inc. (USA)
6.Market Analytics
Exhibits
- Table 1: Percentage Breakdown of Hematological Cancer Cases by Type in The US - 2008e
- Table 2: Percentage Breakdown of Drugs Used in First Line Treatment in European Multiple Myeloma Market -
- Table 3: Percentage Breakdown of Drugs Used in Second Line Treatment in European Multiple Myeloma Market -
- Table 4: Percentage Breakdown of Drugs Used in Third Line Treatment in European Multiple Myeloma Market -
- Table 5: Market Shares of Leading Companies in The US Market for Multiple Myeloma Therapeutics -
- Table 6: Market Shares of Leading Companies in The US Market for Multiple Myeloma Therapeutics - 2013p
- Table 7: Market Shares of Leading Companies in The US Market for Oncology and Hematology - 2008e
- Table 8: Multiple Myeloma Therapeutics Market by Drug in The US: 2007-2015 (Sales in US$ Million)
- Table 9: Percentage Breakdown of Multiple Myeloma Therapeutics Market by Drug in The US for The Years 2009 &
- Table 10: Multiple Myeloma Therapeutics Market by Line of Treatment in The US: 2007-2015 (Sales in US$ Million)
- Table 11: Percentage Breakdown of Multiple Myeloma Therapeutics Market by Line of Treatment in The US for The Years 2009 &
Companies Profiled

Pharmaceutical Market Research

Multiple Myeloma Therapeutics

Multiple Myeloma Therapeutics

Contents

Related products